| Douglas Hunt |
Douglas Hunt currently works at Puma Biotechnology, Inc., as Chief Regulatory Affairs Officer from 2024. Mr. Hunt also formerly worked at Amgen, Inc., as Executive Director-Therapeutic Area from 2000 to 2008, Baxter Healthcare Corp., as Vice President-Global Regulatory Affairs from 2008 to 2015, and ArmaGen, Inc., as VP-Regulatory Affairs & Quality Assurance from 2015 to 2017. Mr. Hunt received his undergraduate degree from the University of Portsmouth. |
| Maximo F. Nougues |
Mr. Maximo F. Nougues is a Chief Financial & Accounting Officer at Puma Biotechnology, Inc. Mr. Nougues was previously employed as a Chief Financial Officer-North America Region by Getinge AB and a Chief Financial Officer & Regional VP-Finance by MAQUET Cardiovascular LLC. He received his graduate degree from Universidad Del Norte Santo Tomas De Aquino and an MBA from Mclaren School of Business. |
| Alan H. Auerbach |
Alan H. Auerbach was the founder of Cougar Biotechnology, Inc. (2003) as President, Chief Executive Officer & Director and Puma Biotechnology, Inc. (2010) as Chairman, President & Chief Executive Officer. Former positions include Chairman, President & Chief Executive Officer at Innovative Acquisitions Corp., Independent Director at Radius Health, Inc. (2011-2017), Vice President & Senior Research Analyst at Diagnostic Products Corp. (2011), Vice President & Senior Research Analyst at Wells Fargo Securities (Old) (2003), and Vice President & Research Analyst at Seidler Cos., Inc. (1997-1998). Education includes an undergraduate degree from Boston University and a graduate degree from the University of Southern California. |
| Alvin F. Wong |
Alvin F. Wong is currently the Chief Scientific Officer at Puma Biotechnology, Inc. He previously worked as the Senior Director-Clinical Development at Proteolix, Inc. from 2007 to 2013. Prior to that, he was a Clinical Professor at UCSF School of Pharmacy from 1976 to 1996. Dr. Wong holds a doctorate degree from The University of California, San Francisco. |
| Brian M. Stuglik |
Brian M. Stuglik was the founder of Proventus Health Solutions LLC, founded in 2016, holding the title of Member. Current jobs include Independent Director at Oncopeptides AB since 2018, Director at Verastem, Inc. since 2023, Independent Director at Puma Biotechnology, Inc. since 2020, and Member of the American Society of Clinical Oncology, Inc., American Association for Cancer Research, and International Association for the Study of Lung Cancer. Former job includes Chief Marketing Officer-Oncology Division & VP at Eli Lilly & Co. from 2009 to 2015. Education includes an undergraduate degree from Purdue University. |
| Allison Dorval |
Allison Dorval currently works at Puma Biotechnology, Inc., as Independent Director from 2021 and Verve Therapeutics, Inc., as Chief Financial Officer. Ms. Dorval also formerly worked at Digitas, Inc., as Finance Director, Jade Biosciences, Inc., as Independent Director from 2021 to 2025, Catalent JNP, Inc., as Vice President & Controller from 2016 to 2017, iBASIS, Inc., as Assistant Controller, Arsenal Medical, Inc., as Chief Financial Officer from 2015 to 2016, Lyra Therapeutics, Inc., as Chief Financial Officer from 2015 to 2016, Insulet Corp., as Chief Financial Officer from 2014 to 2015, PricewaterhouseCoopers LLP, as Principal, and Voyager Therapeutics, Inc., as Chief Financial Officer from 2018 to 2021. Ms. Dorval received her undergraduate degree from the University of Vermont. |
| Troy E. Wilson |
Troy E. Wilson is the founder of Araxes Pharma LLC, serving as Executive Chairman since 2019, founded in 2012. Dr. Wilson is the founder of Avidity Biosciences, Inc., serving as Non-Executive Chairman since 2021, founded in 2012. Dr. Wilson is the founder of Kura Oncology, Inc., serving as Chairman, President, CEO & Chief Financial Officer since 2022, founded in 2014. Dr. Wilson was the founder of Ambrx, Inc., serving as Chief Business Officer, founded in 2003. Dr. Wilson was the founder of Intellikine LLC, serving as President, Chief Executive Officer & Director from 2007 to 2012, founded in 2007. Dr. Wilson is also the founder of Wildcat Discovery Technologies, Inc. Dr. Wilson is currently Executive Chairman of Abintus Bio, Inc. since 2020 and Independent Director of Puma Biotechnology, Inc. since 2013. Former positions include Chairman, President & Chief Executive Officer of Zeta Acquisition Corp. III, Chief Executive Officer of Takeda Pharmaceuticals U.S.A., Inc., Executive Chairman of Wellspring Biosciences LLC from 2019 to 2023, Director of ZP Opco, Inc., Independent Director of Zosano Pharma Corp. from 2014 to 2019, Founding Partner of Presidio Partners, and Vice President-Business Development of Novartis Institute for Functional Genomics, Inc. Education includes a graduate degree from New York University. |
| Adrian M. Senderowicz |
Adrian M. Senderowicz currently works at Puma Biotechnology, Inc., as Independent Director from 2015 and Step Pharma SAS, as Director from 2021. Dr. Senderowicz also formerly worked at AstraZeneca PLC, as Senior Medical Director-Oncology Division from 2008 to 2012, Oncoinvent ASA, as Non-Executive Director, National Institutes of Health, as Head-Prostate Cancer Clinic, US Food & Drug Administration, as Clinical Team Leader-Oncology Division, Tokai Pharmaceuticals, Inc., as Chief Medical Officer & VP-Medical Development from 2012 to 2013, Cerulean Pharma, Inc., as Chief Medical Officer & Senior Vice President from 2015 to 2017, Constellation Pharmaceuticals, Inc., as Chief Medical Officer & Senior Vice President from 2017 to 2020, Ignyta, Inc., as Chief Medical Officer & SVP-Regulatory Affairs from 2014 to 2015, Daré Bioscience, Inc., as Chief Medical Officer & Senior Vice President from 2015 to 2017, and Sanofi, as Vice President-Global Regulatory Oncology from 2013 to 2014. Dr. Senderowicz received his doctorate degree from Universidad de Buenos Aires. |
| Alessandra Cesano |
Alessandra Cesano currently works at Puma Biotechnology, Inc., as Independent Director from 2022, Summit Therapeutics, Inc., as Independent Non-Executive Director from 2022, Zymeworks, Inc., as Independent Director from 2024, American Society of Clinical Oncology, Inc., as Member, American Association for Cancer Research, as Member, American Society of Hematology, as Member, International Society for Biological Therapy of Cancer, as Member, European Society for Medical Oncology, as Member, The European Hematology Association, as Member, and Society For Immunotherapy of Cancer, as Member. Dr. Cesano also formerly worked at Amgen, Inc., as Vice President, Biogen, Inc., as VP & Medical Officer-Oncology Medical Research from 2006 to 2008, Nodality, Inc., as Chief Operating & Medical Officer from 2011 to 2014, The Wistar Institute, as Principal, NS Wind Down Co., Inc., as Chief Medical Officer from 2015 to 2019, ESSA Pharma, Inc., as Chief Medical Officer from 2019 to 2023, and Cleave Therapeutics, Inc., as Chief Medical Officer from 2014 to 2015. Dr. Cesano received her doctorate degree from the University of Turin and undergraduate degree from Istituto Tecnico Economico O. F. Mossotti di Novara. |
| Jay M. Moyes |
Mr. Jay M. Moyes is a Lead Independent Director at Puma Biotechnology, Inc., an Independent Director at BioCardia, Inc., a Managing Member at Drayton Investments LLC and a Member at Utah Association of Certified Public Accountants. He is on the Board of Directors at SINTX Technologies, Inc., Puma Biotechnology, Inc. and BioCardia, Inc. Mr. Moyes was previously employed as a Chief Financial Officer & Treasurer by Sera Prognostics, Inc., an Independent Director by Predictive Technology Group, Inc., an Independent Director by Achieve Life Sciences, Inc., an Independent Director by Integrated Diagnostics, Inc., a Chief Financial Officer by XDx, Inc., an Independent Non-Executive Director by Osiris Therapeutics, Inc., a Trustee by Utah Life Science Association, a Chief Financial Officer by Myriad Genetics, Inc., a Chief Financial Officer & Vice President-Finance by Genmarks, Inc., and a Senior Manager by KPMG LLP. He also served on the board at BioCardia, Inc. /Old/. He received his undergraduate degree from Weber State University and an MBA from the University of Utah. |
| Michael Patrick Miller |
Michael Patrick Miller currently works at Puma Biotechnology, Inc., as Independent Director from 2018, Zane Beadles Parade Foundation, as Director, and BioXcel Therapeutics, Inc., as Independent Director from 2022. Mr. Miller also formerly worked at The Leukemia & Lymphoma Society, Inc., as Director, Allena Pharmaceuticals, Inc., as Director, ALZA Corp., as Vice President-Urology Business from 1997 to 2001, Genentech, Inc., as Vice President-Sales & Marketing from 2006 to 2010, Cellegy Pharmaceuticals, Inc., as Vice President-Commercial Operations, VIVUS, Inc., as Chief Commercial Officer & Senior Vice President from 2010 to 2014, Connetics Corp., as Chief Commercial Officer & SVP-Sales & Marketing from 2003 to 2005, and Jazz Pharmaceuticals Plc, as Executive Vice President-Commercial from 2017 to 2020. Mr. Miller received his undergraduate degree and graduate degree from Duke University, Masters Business Admin degree from San Francisco State University, and undergraduate degree from the University of San Francisco. |
